Cargando…

Su1493: COVID-19 RELATED THROMBOTIC, CARDIOVASCULAR, AND RENAL COMPLICATIONS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: DATA FROM AN INTERNATIONAL REGISTRY

Detalles Bibliográficos
Autores principales:	Spiera, Emily, Brenner, Erica J., Zhang, Xian, Faye, Adam S., Agrawal, Manasi, Ganjian, Danielle Y., Colombel, Jean Frederic, Kappelman, Michael, Kornbluth, Asher, Ungaro, Ryan C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AGA Institute. Published by Elsevier Inc. 2022
Materias:	AGA Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9212288/ http://dx.doi.org/10.1016/S0016-5085(22)61415-X

Ejemplares similares

Outcomes of COVID-19 Infections in Vaccinated Patients with Inflammatory Bowel Disease: Data From an International Registry
por: Spiera, Emily, et al.
Publicado: (2022)

COVID-19 INFECTIONS IN VACCINATED PATIENTS WITH INFLAMMATORY BOWEL DISEASE: OUTCOMES AND RISK FACTORS FOR SEVERE DISEASE
por: Spiera, Emily, et al.
Publicado: (2022)

Fr498 NEW GASTROINTESTINAL SYMPTOMS ARE COMMON IN INFLAMMATORY BOWEL DISEASE PATIENTS WITH COVID-19: DATA FROM AN INTERNATIONAL REGISTRY
por: Ungaro, Ryan C., et al.
Publicado: (2021)

Fr494 THE IMPACT OF VEDOLIZUMAB THERAPY ON COVID-19 OUTCOMES IN ADULT IBD PATIENTS IN THE SECURE-IBD REGISTRY
por: Agrawal, Manasi, et al.
Publicado: (2021)

Fr496 THE EFFECTS OF COMORBIDITIES ON COVID-19 OUTCOMES AMONG PATIENTS WITH INFLAMMATORY BOWEL DISEASE
por: Parekh, Rajen, et al.
Publicado: (2021)

Fr509 COVID-19 OUTCOMES AMONG RACIAL AND ETHNIC MINORITY INDIVIDUALS WITH INFLAMMATORY BOWEL DISEASES IN THE UNITED STATES
por: Agrawal, Manasi, et al.
Publicado: (2021)

Fr491 MULTIVARIABLE PREDICTION MODELS FOR HOSPITALIZATION, VENTILATION, AND DEATH FROM COVID-19 IN IBD PATIENTS
por: Sperger, John, et al.
Publicado: (2021)

Sa502 THE FIRST AND SECOND WAVE OF COVID-19 IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A TEMPORAL TREND ANALYSIS
por: Kaplan, Gilaad, et al.
Publicado: (2021)

Impact of Medications on COVID-19 Outcomes in Inflammatory Bowel Disease: Analysis of More Than 6000 Patients From an International Registry
por: Ungaro, Ryan C., et al.
Publicado: (2022)

Su1482: SCOUT IBD: SURVEILLANCE OF COVID-19 IMPACT ON LONG-TERM OUTCOMES IN IBD
por: Hong, Simon J., et al.
Publicado: (2022)

Su1483: COVID-19 VACCINES ARE HIGHLY EFFECTIVE IN PATIENTS WITH IBD: OUTCOMES FROM THE SCOUT IBD COHORT
por: Hong, Simon J., et al.
Publicado: (2022)

Su1492: STRONG HUMORAL IMMUNE RESPONSE TO SARS-COV-2 VACCINE ADDITIONAL DOSE AMONG PATIENTS WITH INFLAMMATORY BOWEL DISEASES
por: Kappelman, Michael, et al.
Publicado: (2022)

The Impact of Vedolizumab on COVID-19 Outcomes Among Adult IBD Patients in the SECURE-IBD Registry
por: Agrawal, Manasi, et al.
Publicado: (2021)

Presence of Comorbidities Associated with Severe Coronavirus Infection in Patients with Inflammatory Bowel Disease
por: Parekh, Rajen, et al.
Publicado: (2021)

Characteristics and Outcomes of IBD Patients with COVID-19 on Tofacitinib Therapy in the SECURE-IBD Registry
por: Agrawal, Manasi, et al.
Publicado: (2020)

Su1480: TREATMENT-EMERGENT COVID-19 INFECTIONS IN OZANIMOD ULCERATIVE COLITIS AND MULTIPLE SCLEROSIS CLINICAL TRIALS
por: Ungaro, Ryan C., et al.
Publicado: (2022)

Su1495: COVID-19 VACCINE HESITANCY REMAINS HIGH IN INFLAMMATORY BOWEL DISEASE PATIENTS
por: Kwon, Hyuk Joon, et al.
Publicado: (2022)

Su1491: ATTITUDES AND PREDICTORS OF COVID-19 VACCINE UPTAKE IN INDIVIDUALS WITH INFLAMMATORY BOWEL DISEASE
por: Zhang, Eva, et al.
Publicado: (2022)

Su1498: SAFETY OF COVID-19 VACCINATION IN INFLAMMATORY BOWEL DISEASE PATIENTS ON BIOLOGIC THERAPY
por: Garrido, Isabel, et al.
Publicado: (2022)

Su1189 SAFETY OF IMMUNE CHECKPOINT INHIBITORS IN PATIENTS WITH PREEXISTING INFLAMMATORY BOWEL DISEASE AND MICROSCOPIC COLITIS
por: Grover, Shilpa, et al.
Publicado: (2020)

Su1487: IMPACT OF INFLAMMATORY BOWEL DISEASE THERAPIES ON DURABILITY OF HUMORAL RESPONSE TO SARS COV-2 VACCINATION
por: Charilaou, Paris, et al.
Publicado: (2022)

Su1489: HUMORAL IMMUNOGENICITY OF THREE SARS-COV-2 MRNA VACCINE DOSES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
por: Schell, Trevor, et al.
Publicado: (2022)

Su1075: SIMILAR RISK OF INFECTION WITH SARS-COV-2 IN IMMUNOCOMPROMISED AND IMMUNOCOMPETENT PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND HEALTHY CONTROLS
por: Kante, Bhaskar, et al.
Publicado: (2022)

Su1484: SEROLOGICAL RESPONSES TO SARS-COV-2 VACCINATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A PROSPECTIVE COHORT STUDY
por: Quan, Joshua, et al.
Publicado: (2022)

Sa1061: CROSS-SECTIONAL AND LONGITUDINAL ASCERTAINMENT OF PATIENTS WITH IBD'S PERCEPTIONS AND EXPERIENCES DURING COVID-19: CLAPPED COVID-19
por: Lee, Hanbich, et al.
Publicado: (2022)

Su093 GUT-BRAIN AXIS AND IRRITABLE BOWEL SYNDROME DURING SARS COV-2 PANDEMIC. A SURVEY BASED STUDY.
por: Piskorz, Maria, et al.
Publicado: (2021)

Su1499: IMMUNOMODULATORS ARE PROTECTIVE AGAINST SEVERE COVID 19: RESULTS FROM A LARGE MULTICENTRE COHORT OF INFLAMMATORY BOWEL DISEASE PATIENTS
por: Vuitton, Lucine, et al.
Publicado: (2022)

Su1486: INCREASED RISK OF VENOUS THROMBOEMBOLISM AMONG HOSPITALIZED INFLAMMATORY BOWEL DISEASE PATIENTS WITH EXPOSURE TO SEVERE ACURE RESPIRATORY SYNDROME CORONAVIRUS 2
por: Kumar, Rashmi, et al.
Publicado: (2022)

Su1611: POOR RESPONSE TO ANTI-SARS-COV-2 VACCINATION IN IMMUNOSUPPRESSED INFLAMMATORY BOWEL DISEASE PATIENTS IS ASSOCIATED WITH ALTERED GUT MICROBIOTA FUNCTION
por: Alexander, James L., et al.
Publicado: (2022)

EP1269: INTERIM ANALYSIS OF A MULTICENTER REGISTRY STUDY OF COVID-19 INFECTED PATIENTS WITH INFLAMMATORY BOWEL DISEASE IN JAPAN (J-COSMOS).
por: Hayashi, Yuki, et al.
Publicado: (2022)

COVID-19 mRNA Vaccine Short-Term Safety in Patients With Inflammatory Bowel Disease
por: Spiera, Emily, et al.
Publicado: (2022)

1163: BOTH VEDOLIZUMAB AND ANTI-TNF THERAPY ARE ASSOCIATED WITH ATTENUATION OF SEROLOGICAL AND NEUTRALIZING RESPONSES TO SARS-COV-2 INFECTION IN INFLAMMATORY BOWEL DISEASE
por: Wellens, Judith, et al.
Publicado: (2022)

Su1490: COVID-19: A PREVALENCE RATE TWO TIMES LOWER THAN THAT OF THE GENERAL POPULATION IN FRENCH PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH INTRAVENOUS BIOLOGIC AGENTS
por: Lelong, Margaux, et al.
Publicado: (2022)

Su1488: WITHIN 6 MONTHS FROM COVID-19 BNT162B2 VACCINE PATIENTS WITH INFLAMMATORY BOWEL DISEASES TREATED WITH ANTI-TNFα HAVE SIGNIFICANTLY LOWER SEROLOGIC RESPONSES
por: Rabinowitz, Keren M., et al.
Publicado: (2022)

Physician Practice Patterns in Holding Inflammatory Bowel Disease Medications due to COVID-19, in the SECURE-IBD Registry
por: Agrawal, Manasi, et al.
Publicado: (2020)

Su1094: HOSPITILISATIONS FOR NOROVIRUS DECREASE DURING THE COVID-19 PANDEMIC
por: Gottlieb, Max T., et al.
Publicado: (2022)

Su1076: DIVERTICULOSIS IS ASSOCIATED WITH INTERNAL HEMORRHOIDS ON COLONOSCOPY: POSSIBLE CLUES TO ETIOLOGY.
por: Sninsky, Jared A., et al.
Publicado: (2022)

Tu1551: PATIENTS WITH INFLAMMATORY BOWEL DISEASES HAVE IMPAIRED ANTIBODY PRODUCTION AFTER ANTI-SARS-COV-2 VACCINATION, ESPECIALLY THOSE ON ANTI-TNFα OR COMBINATION TREATMENT OF BIOLOGICS PLUS IMMUNOMODULATORS: RESULTS FROM A PANHELLENIC REGISTRY
por: Zacharopoulou, Eirini, et al.
Publicado: (2022)

Su083 PERSISTENCE OF GASTROINTESTINAL SYMPTOMS AFTER HOSPITALIZATION FOR COVID-19: PREVALENCE AND RISK FACTORS
por: Blackett, John W., et al.
Publicado: (2021)

Su1000: IMPACT OF COVID-19 PANDEMIC AND SOCIAL DETERMINANTS OF HEALTH ON UTILIZATION OF TELEHEALTH SERVICES
por: Sanaka, Harsha, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_u6fnbiklbepdi26e6pujj1vmue